The Next Cox-2 Battle: Merck, Novartis Drugs Face Vocal Resistance

Novartis AG and Merck & Co. Inc. beware: Steven Nissen doesn't want your investigational cox-2 inhibitors to win approval from the Food & Drug Administration.

More from Clinical Trials

More from R&D